Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | - |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.47 | 2.02 |
NAV | ₹28.97 | ₹62.26 |
Fund Started | 10 Jun 2011 | 18 Jun 2012 |
Fund Size | ₹108.06 Cr | ₹3015.47 Cr |
Exit Load | Exit load of 1%, if redeemed within 90 days | Exit load of 1% if redeemed within 1 month. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 19.12% | 7.98% |
3 Year | 8.59% | 14.96% |
5 Year | 8.19% | 13.50% |
1 Year
3 Year
5 Year
Equity | 0.00% | 98.01% |
Cash | 99.16% | 1.99% |
Equity
Cash
Top 10 Holdings | - |
|
Top 10 Holdings
Name | Assets |
---|---|
Veeva Systems Inc. | 3.04% |
West Pharmaceutical Services Inc | 2.81% |
Huntington Ingalls Industries Inc. (US) | 2.68% |
Brown-Forman Corp | 2.66% |
Allegion PLC | 2.47% |
Zimmer Biomet Holdings | 2.46% |
Microchip Technology Inc. (USA) | 2.44% |
Pfizer INC | 2.42% |
Monolithic Power Systems Inc. | 2.42% |
Corteva Inc. | 2.41% |
Name | Bharat Lahoti | Ritesh Lunawat |
Start Date | 18 Sep 2017 | 28 Dec 2020 |
Name
Start Date
Description | The scheme seeks to provide long term capital growth by investing predominantly in JPMorgan Funds - JF ASEAN Equity Fund, an equity fund which invests primarily in companies of countries which are members of the Association of South East Asian Nations (ASEAN). | The investment objective of ICICI Prudential US Bluechip Equity Fund is to provide long term capital appreciation to investors by primarily investing in equity and equity related securities of companies listed on recognized stock exchanges in the United States of America. The Scheme shall also invest in ADRs/GDRs issued by Indian and foreign companies. |
Launch Date | 10 Jun 2011 | 18 Jun 2012 |
Description
Launch Date